International strategic alliances for collaborative product Innovation: An agent-based scenario analysis in biopharmaceutical industry

The lack of ability, knowledge, and resources at a national level leads companies to choose international strategic alliances (ISAs) as an appropriate solution to enter the global markets. In this regard, selecting appropriate partners is a fundamental step in reducing the risks and costs of these a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of business research 2023-03, Vol.158, p.113663, Article 113663
Hauptverfasser: Esmaelnezhad, Danial, Taghizadeh-Yazdi, Mohammadreza, Amoozad Mahdiraji, Hannan, Vrontis, Demetris
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The lack of ability, knowledge, and resources at a national level leads companies to choose international strategic alliances (ISAs) as an appropriate solution to enter the global markets. In this regard, selecting appropriate partners is a fundamental step in reducing the risks and costs of these alliances. This article analyzes international partner selection scenarios using agent-based simulations in Iran's biopharmaceutical industry. In line with the goal of this research, a complete understanding of the failure and success of collaboration product innovation is presented. First, the critical/key success factors (KSFs) in international strategic alliances were identified through a literature review (LR) and screened via Fuzzy Delphi. Next, selected factors were weighted by fuzzy SWARA (Stepwise Weight Assessment Ratio Analysis) and considered as simulation inputs for international partner selection. The simulation results indicated the critical role of the knowledge-matching degree and complementary resources and the insignificant impact of the company's reputation, government support, and experience in the international alliance. Furthermore, we found that pharmaceutical and biotech companies should emphasize their partner's complementary resources and develop an evaluation system to measure the knowledge-matching degree of their foreign partners in ISA. Eventually, this paper provides practical and applied solutions for biopharmaceutical industry managers to analyze business partners. The article also adds to the debate on ISAs in biopharmaceutical industries.
ISSN:0148-2963
1873-7978
DOI:10.1016/j.jbusres.2023.113663